Article Text

Download PDFPDF
Systematic review
Adding atypical antipsychotics to antidepressants increases response in treatment-resistant major depression but increases discontinuation as a result of adverse events
  1. Gabor I Keitner
  1. Gabor I Keitner
    Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA; GKeitner{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science

The outcome of treatment for major depression is suboptimal. Only a minority of patients (<30%) achieve remission with the first antidepressant, and most relapse. Each subsequent treatment trial yields even lower rates of remission. Psychotherapy, similarly, results in a 30% remission rate and a 50% improvement in 50% of depressed patients. Between 15% and 30% of depressed patients have a chronic course of illness despite adequate treatment trials. There is, therefore, a well-established need for new approaches for depressed patients who have not responded well to commonly used antidepressant treatments.

The development of second-generation antipsychotic medications with arguably more benign side effect profiles has led to a renewed interest in their use for the treatment of depression. …

View Full Text


  • Competing interests None.